Abstract
Immune-mediated diarrhea and colitis (IMDC) is a common adverse event in cancer patients receiving immune checkpoint inhibitors (ICIs). Gastrointestinal (GI) infections can co-occur with IMDC, and its impact on the course and outcome of IMDC remains unclear. We retrospectively reviewed cancer patients who received ICIs and developed IMDC between January 2015 and September 2019. GI multiplex panel is used to assess GI infection. The study group included patients with positive infection except those who are only positive for Clostridioides difficile or cytomegalovirus. The control group is IMDC patients with negative infection using frequency matching. Patients' disease course and outcome were compared between groups. A total of 72 patients with IMDC were included: 22 in the study group and 50 as control. Escherichia coli of different pathotypes was observed in 17 patients. Five patients had viral infections, for example, adenovirus, norovirus, and sapovirus. Patients with GI infections more frequently had grade 3 or 4 colitis (43% vs. 18%, P=0.041). Overall, GI infections were not associated with different risks of IMDC recurrence or overall survival. Antibiotics treatment did not affect the requirement for infliximab or vedoliz...Continue Reading
References
Jul 7, 1997·The Journal of Experimental Medicine·S R BennettW R Heath
Jul 17, 2004·European Journal of Gastroenterology & Hepatology·Maria MylonakiDavid S Rampton
Oct 8, 2004·Critical Care : the Official Journal of the Critical Care Forum·Mark D WilliamsWalter Linde-Zwirble
Mar 11, 2009·Journal of Pediatric Gastroenterology and Nutrition·Raheel R KhanJohn N Udall
Dec 12, 2012·Experimental and Therapeutic Medicine·Sheng-Lan WangChang-Qing Yang
Jan 27, 2016·World Journal of Gastroenterology : WJG·Orna NitzanWalid Saliba
Apr 30, 2016·Science·Martin J Blaser
May 6, 2017·Nature Medicine·Carl H JuneJeffrey A Bluestone
Sep 26, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L KhojaA R Hansen
Oct 21, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Andi L ShaneLarry K Pickering
Nov 23, 2017·Journal for Immunotherapy of Cancer·I PuzanovUNKNOWN Society for Immunotherapy of Cancer Toxicity Management Working Group
Feb 15, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie R BrahmerUNKNOWN National Comprehensive Cancer Network
Apr 5, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L DerosaB Routy
Nov 14, 2018·Nature Medicine·Yinghong WangRobert R Jenq
Sep 7, 2019·Journal for Immunotherapy of Cancer·Hamzah Abu-SbeihYinghong Wang